JP2020512820A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512820A5 JP2020512820A5 JP2019554816A JP2019554816A JP2020512820A5 JP 2020512820 A5 JP2020512820 A5 JP 2020512820A5 JP 2019554816 A JP2019554816 A JP 2019554816A JP 2019554816 A JP2019554816 A JP 2019554816A JP 2020512820 A5 JP2020512820 A5 JP 2020512820A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- human igm
- constant region
- modified human
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023062508A JP2023085503A (ja) | 2017-04-07 | 2023-04-07 | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 |
| JP2024175523A JP2024177479A (ja) | 2017-04-07 | 2024-10-07 | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483087P | 2017-04-07 | 2017-04-07 | |
| US62/483,087 | 2017-04-07 | ||
| PCT/US2018/026474 WO2018187702A2 (en) | 2017-04-07 | 2018-04-06 | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023062508A Division JP2023085503A (ja) | 2017-04-07 | 2023-04-07 | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020512820A JP2020512820A (ja) | 2020-04-30 |
| JP2020512820A5 true JP2020512820A5 (https=) | 2021-10-07 |
Family
ID=63713537
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554816A Withdrawn JP2020512820A (ja) | 2017-04-07 | 2018-04-06 | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 |
| JP2023062508A Pending JP2023085503A (ja) | 2017-04-07 | 2023-04-07 | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 |
| JP2024175523A Pending JP2024177479A (ja) | 2017-04-07 | 2024-10-07 | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023062508A Pending JP2023085503A (ja) | 2017-04-07 | 2023-04-07 | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 |
| JP2024175523A Pending JP2024177479A (ja) | 2017-04-07 | 2024-10-07 | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11401337B2 (https=) |
| EP (1) | EP3607091A4 (https=) |
| JP (3) | JP2020512820A (https=) |
| KR (1) | KR102696143B1 (https=) |
| CN (1) | CN110536900B (https=) |
| AU (1) | AU2018248336B2 (https=) |
| CA (1) | CA3055790A1 (https=) |
| IL (1) | IL268901B2 (https=) |
| MX (1) | MX2019011986A (https=) |
| SG (1) | SG11201908051RA (https=) |
| WO (1) | WO2018187702A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3105250B1 (en) | 2014-02-10 | 2020-08-05 | IGM Biosciences, Inc. | Iga multi-specific binding molecules |
| PL3560954T3 (pl) | 2014-04-03 | 2021-12-13 | Igm Biosciences, Inc. | Zmodyfikowany łańcuch J |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| EP3957738A1 (en) | 2015-03-04 | 2022-02-23 | IGM Biosciences, Inc. | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| CN107847591B (zh) | 2015-04-17 | 2023-07-28 | Igm生物科学股份有限公司 | 多价人免疫缺陷病毒抗原结合分子及其应用 |
| EP3355913B1 (en) | 2015-09-30 | 2024-10-30 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| SG11201809336QA (en) | 2016-05-09 | 2018-11-29 | Igm Biosciences Inc | Anti-pd-l1 antibodies |
| MX2019011986A (es) * | 2017-04-07 | 2019-11-07 | Igm Biosciences Inc | Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas. |
| MX2020009069A (es) | 2018-03-01 | 2020-10-08 | Igm Biosciences Inc | Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero. |
| US20210380701A1 (en) * | 2018-10-23 | 2021-12-09 | Igm Biosciences, Inc. | MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES |
| JP2022544405A (ja) * | 2019-08-15 | 2022-10-18 | アイジーエム バイオサイエンシズ インコーポレイテッド | 免疫刺激性多量体型結合分子 |
| KR20220045030A (ko) * | 2019-08-17 | 2022-04-12 | 아이쥐엠 바이오사이언스 인코포레이티드 | 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도 |
| AU2020351205A1 (en) * | 2019-09-19 | 2022-04-14 | Igm Biosciences, Inc. | Multimeric antibodies with enhanced selectivity for cells with high target density |
| EP4139362A2 (en) | 2020-04-22 | 2023-03-01 | IGM Biosciences Inc. | Pd-1 agonist multimeric binding molecules |
| US20240076392A1 (en) * | 2021-02-17 | 2024-03-07 | Igm Biosciences, Inc. | Anti-cd123 binding molecules and uses thereof |
| AU2023216348A1 (en) * | 2022-02-03 | 2024-06-20 | Igm Biosciences, Inc. | Anti-cd38 binding molecules and uses thereof |
| US20250326844A1 (en) | 2022-04-07 | 2025-10-23 | Repertoire Immune Medicines, Inc. | T cell receptor multimers and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256771A (en) | 1990-04-03 | 1993-10-26 | Miles Inc. | Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| US20050014932A1 (en) | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
| US20150071948A1 (en) * | 2003-09-26 | 2015-03-12 | Gregory Alan Lazar | Novel immunoglobulin variants |
| CN1922316B (zh) | 2003-12-25 | 2011-03-23 | 协和发酵麒麟株式会社 | 抗cd40抗体突变体 |
| DK1814913T3 (en) | 2004-11-05 | 2015-09-28 | Univ Leland Stanford Junior | ANTIBODY-INDUCED CELL membrane damage. |
| CA2780221A1 (en) * | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| EP2760891B1 (en) * | 2011-09-26 | 2018-11-07 | JN Biosciences LLC | Hybrid constant regions |
| WO2013120012A2 (en) | 2012-02-08 | 2013-08-15 | Igm Biosciences Inc. | Cdim binding proteins and uses thereof |
| CA2922830A1 (en) | 2013-09-05 | 2015-04-16 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
| US9416496B2 (en) * | 2013-10-16 | 2016-08-16 | Georgia-Pacific Consumer Products Lp | Method for reducing the bulk and increasing the density of a tissue product |
| EP3105250B1 (en) | 2014-02-10 | 2020-08-05 | IGM Biosciences, Inc. | Iga multi-specific binding molecules |
| WO2015129651A1 (ja) * | 2014-02-25 | 2015-09-03 | 富士レビオ株式会社 | 改変単量体ＩｇＭ |
| PL3560954T3 (pl) | 2014-04-03 | 2021-12-13 | Igm Biosciences, Inc. | Zmodyfikowany łańcuch J |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| EP3957738A1 (en) | 2015-03-04 | 2022-02-23 | IGM Biosciences, Inc. | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| CN107847591B (zh) | 2015-04-17 | 2023-07-28 | Igm生物科学股份有限公司 | 多价人免疫缺陷病毒抗原结合分子及其应用 |
| WO2017053469A2 (en) * | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| EP3355913B1 (en) | 2015-09-30 | 2024-10-30 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| CN105441455B (zh) * | 2015-10-21 | 2020-08-28 | 重庆金迈博生物科技有限公司 | 一种嵌合核酸分子及其在人源化抗体制备中的应用 |
| SG11201809336QA (en) | 2016-05-09 | 2018-11-29 | Igm Biosciences Inc | Anti-pd-l1 antibodies |
| AU2017299608A1 (en) | 2016-07-20 | 2019-02-07 | Igm Biosciences, Inc. | Multimeric CD137/4-1BB binding molecules and uses thereof |
| JP2019530640A (ja) | 2016-07-20 | 2019-10-24 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多量体ｏｘ４０結合分子及びその使用 |
| MX2019000799A (es) | 2016-07-20 | 2019-06-03 | Igm Biosciences Inc | Moleculas de union a gitr multimericas y usos de las mismas. |
| EP3496536A4 (en) | 2016-07-20 | 2020-02-12 | IGM Biosciences, Inc. | MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF |
| MX2019011986A (es) * | 2017-04-07 | 2019-11-07 | Igm Biosciences Inc | Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas. |
| EP3759229A4 (en) | 2018-02-26 | 2021-12-29 | IGM Biosciences Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
| MX2020009069A (es) | 2018-03-01 | 2020-10-08 | Igm Biosciences Inc | Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero. |
| US20210380701A1 (en) | 2018-10-23 | 2021-12-09 | Igm Biosciences, Inc. | MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES |
-
2018
- 2018-04-06 MX MX2019011986A patent/MX2019011986A/es unknown
- 2018-04-06 EP EP18781914.9A patent/EP3607091A4/en active Pending
- 2018-04-06 KR KR1020197030684A patent/KR102696143B1/ko active Active
- 2018-04-06 IL IL268901A patent/IL268901B2/en unknown
- 2018-04-06 US US16/500,292 patent/US11401337B2/en active Active
- 2018-04-06 JP JP2019554816A patent/JP2020512820A/ja not_active Withdrawn
- 2018-04-06 CA CA3055790A patent/CA3055790A1/en active Pending
- 2018-04-06 AU AU2018248336A patent/AU2018248336B2/en active Active
- 2018-04-06 SG SG11201908051RA patent/SG11201908051RA/en unknown
- 2018-04-06 CN CN201880022469.1A patent/CN110536900B/zh active Active
- 2018-04-06 WO PCT/US2018/026474 patent/WO2018187702A2/en not_active Ceased
-
2022
- 2022-06-10 US US17/806,339 patent/US20220340676A1/en not_active Abandoned
-
2023
- 2023-04-07 JP JP2023062508A patent/JP2023085503A/ja active Pending
-
2024
- 2024-10-07 JP JP2024175523A patent/JP2024177479A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512820A5 (https=) | ||
| CN113195516B (zh) | 由特异性结合物识别的表位标签 | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JP2020503885A5 (https=) | ||
| JP2018528786A5 (https=) | ||
| JP2019528077A5 (https=) | ||
| MX2020011391A (es) | Anticuerpo bcma humanizado y linfocitos t car-bcma. | |
| JP2018519296A5 (https=) | ||
| IL275743A (en) | New bispecific format suitable for use in high-through-put screening | |
| JP2024177479A (ja) | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 | |
| JP2017526350A5 (https=) | ||
| JP2017522891A5 (https=) | ||
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| JP5142265B2 (ja) | 抗モータリン抗体のパラトープ及びエピトープ | |
| FI3665192T3 (fi) | Muunneltuja transferriinireseptoria sitovia polypeptidejä | |
| CA2977350A1 (en) | Bivalent antibody directed against nkg2d and tumor associated antigens | |
| HRP20251051T1 (hr) | Anti-cd3 antitijelo i molekula koja sadrži navedeno antitijelo | |
| CN114450395A (zh) | Lockr介导的car t细胞募集 | |
| JP2018507254A5 (https=) | ||
| JP2021520209A (ja) | 癌患者における腫瘍抗原を検出するための診断アッセイ | |
| PH12018502293B1 (en) | Humanized anti-basigin antibodies and the use thereof | |
| JP2018148915A5 (https=) | ||
| JP2018504903A5 (https=) | ||
| JP2017509323A5 (https=) | ||
| WO2023060137A3 (en) | Methods and compositions comprising b7-h3 binding polypeptides |